FDA permits use of Sarepta Therapeutics’ Duchenne therapy in younger patients after short-lived halt - statnews.com
The FDA said it was clearing the way for Sarepta Therapeutics to resume shipments of its gene therapy for Duchenne muscular dystrophy to some patients.
Comments